Investors & Media
Phathom Pharmaceuticals is a late clinical-stage biopharmaceutical company focused on developing and commercializing new treatments for GI disorders. We have licensed the exclusive rights in the United States, Europe, and Canada to vonoprazan, a potassium competitive acid blocker (P-CAB) in late clinical-stage development for the treatment of gastric acid-related disorders. Vonoprazan has the potential to be the first gastric anti-secretory agent from a new class approved in the United States, Europe, or Canada in over 30 years.
We have initiated a Phase 3 clinical trial for the treatment of erosive GERD, a Phase 2 trial to evaluate various doses of vonoprazan as an on-demand therapy for patients with nonerosive reflux disease (NERD), and released topline results from a Phase 3 clinical trial for the treatment of H. pylori infection.
Phathom has assembled a team of seasoned gastrointestinal and pharmaceutical industry experts with deep expertise in developing GI therapeutics, including anti-secretory agents.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
Oct 18, 2021 at 8:30 AM EDT
Sep 14, 2021 at 11:00 AM EDT